ATE357254T1 - Adjuvanskombinationen von liposomen und mycobakteriellen lipiden für immunisierungszusammensetzungen und impfstoffe - Google Patents
Adjuvanskombinationen von liposomen und mycobakteriellen lipiden für immunisierungszusammensetzungen und impfstoffeInfo
- Publication number
- ATE357254T1 ATE357254T1 AT04738985T AT04738985T ATE357254T1 AT E357254 T1 ATE357254 T1 AT E357254T1 AT 04738985 T AT04738985 T AT 04738985T AT 04738985 T AT04738985 T AT 04738985T AT E357254 T1 ATE357254 T1 AT E357254T1
- Authority
- AT
- Austria
- Prior art keywords
- lipids
- vaccines
- liposomes
- surfactant
- adjuvant combinations
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title abstract 8
- 239000002671 adjuvant Substances 0.000 title 1
- 230000003053 immunization Effects 0.000 title 1
- 238000002649 immunization Methods 0.000 title 1
- 239000002502 liposome Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 abstract 2
- 239000004094 surface-active agent Substances 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000021633 leukocyte mediated immunity Effects 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 239000012646 vaccine adjuvant Substances 0.000 abstract 1
- 229940124931 vaccine adjuvant Drugs 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B5/00—Optical elements other than lenses
- G02B5/30—Polarising elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polarising Elements (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200301046 | 2003-07-09 | ||
| DKPA200301403 | 2003-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE357254T1 true ATE357254T1 (de) | 2007-04-15 |
Family
ID=34066437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04738985T ATE357254T1 (de) | 2003-07-09 | 2004-07-07 | Adjuvanskombinationen von liposomen und mycobakteriellen lipiden für immunisierungszusammensetzungen und impfstoffe |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20060286128A1 (de) |
| EP (1) | EP1648504B1 (de) |
| KR (1) | KR100992646B1 (de) |
| AT (1) | ATE357254T1 (de) |
| AU (1) | AU2004255393B2 (de) |
| CA (1) | CA2531825C (de) |
| DE (1) | DE602004005460T2 (de) |
| DK (1) | DK1648504T3 (de) |
| ES (1) | ES2285466T3 (de) |
| WO (1) | WO2005004911A2 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ581306A (en) * | 2004-11-16 | 2011-03-31 | Crucell Holland Bv | Multivalent vaccines comprising recombinant viral vectors |
| US7774539B2 (en) * | 2007-02-07 | 2010-08-10 | Lenovo (Singapore) Pte. Ltd | Preservation of hard drive data via dynamic band boundary definition |
| PL2167124T3 (pl) * | 2007-06-29 | 2012-12-31 | Statens Seruminstitut | Zastosowanie monomikoliloglicerolu (MMG) jako adiuwantu |
| EP4241767B1 (de) | 2008-11-10 | 2024-10-23 | Arbutus Biopharma Corporation | Neuartige lipide und zusammensetzungen zur verabreichung von therapeutika |
| WO2010085896A1 (en) | 2009-01-29 | 2010-08-05 | British Columbia Cancer Agency Branch | Compositions comprising chlamydia antigens |
| WO2011031139A1 (en) | 2009-09-09 | 2011-03-17 | Universiteit Utrecht Holding B.V. | An ataq protein or a part thereof as a vaccine |
| SA110310855B1 (ar) | 2009-11-13 | 2014-09-16 | Laboratories Leti S L Unipersonal | استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي |
| JP5986576B2 (ja) | 2010-11-10 | 2016-09-06 | ラボラトリオス レティ，エセ．エレ． | 新規アジュバント |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| CN108949772A (zh) | 2012-04-02 | 2018-12-07 | 现代泰克斯公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US20160194625A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| EP3349790A1 (de) | 2015-09-18 | 2018-07-25 | Rijksuniversiteit Groningen | Langkettiges inulin zur stimulierung einer immunantwort |
| MD3718565T2 (ro) | 2015-10-22 | 2022-09-30 | Modernatx Inc | Vaccinuri împotriva virusului respirator |
| CN116917470A (zh) | 2020-10-14 | 2023-10-20 | 达冕生物有限公司 | PAN-RAS mRNA癌症疫苗 |
| US20220226465A1 (en) | 2021-01-18 | 2022-07-21 | ConserV Bioscience | Coronavirus Immunogenic Compositions, Methods and Uses Thereof |
| EP4392560B1 (de) | 2021-08-27 | 2026-03-11 | Peking University | Konstrukte und verfahren zur herstellung von zirkulärer rna |
| WO2023161350A1 (en) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| EP4520345A1 (de) | 2023-09-06 | 2025-03-12 | Myneo Nv | Produkt |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9409985D0 (en) * | 1994-05-18 | 1994-07-06 | Medical Res Council | Vaccine against mycobacterial infections |
| US6218166B1 (en) * | 1994-12-09 | 2001-04-17 | John Wayne Cancer Institute | Adjuvant incorporation into antigen carrying cells: compositions and methods |
| US7037510B2 (en) * | 1997-04-18 | 2006-05-02 | Statens Serum Institut | Hybrids of M. tuberculosis antigens |
| US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
| EP1183044B1 (de) * | 1999-05-12 | 2007-10-10 | Statens Serum Institut | Adjuvanskombinationen zur immunisierung und vakzine |
| AU2001251316A1 (en) * | 2000-04-04 | 2001-10-15 | Antigenics Inc. | Isolated and purified nonpeptide antigens from mycobacterium tuberculosis |
| GB0106985D0 (en) * | 2001-03-20 | 2001-05-09 | Stanford Rook Ltd | Immunotherapeutic agent |
| GB0106986D0 (en) * | 2001-03-20 | 2001-05-09 | Stanford Rook Ltd | Immunotherapeutic agent |
| EP1416959B1 (de) * | 2001-08-03 | 2010-06-23 | National Research Council Of Canada | Aus mycobacterium extrahierbaren lipide hergestellete liposomen |
-
2003
- 2003-12-03 KR KR1020067010858A patent/KR100992646B1/ko not_active Expired - Fee Related
-
2004
- 2004-07-07 DK DK04738985T patent/DK1648504T3/da active
- 2004-07-07 WO PCT/DK2004/000488 patent/WO2005004911A2/en not_active Ceased
- 2004-07-07 US US10/563,731 patent/US20060286128A1/en not_active Abandoned
- 2004-07-07 ES ES04738985T patent/ES2285466T3/es not_active Expired - Lifetime
- 2004-07-07 EP EP04738985A patent/EP1648504B1/de not_active Expired - Lifetime
- 2004-07-07 CA CA2531825A patent/CA2531825C/en not_active Expired - Lifetime
- 2004-07-07 AT AT04738985T patent/ATE357254T1/de not_active IP Right Cessation
- 2004-07-07 DE DE602004005460T patent/DE602004005460T2/de not_active Expired - Lifetime
- 2004-07-07 AU AU2004255393A patent/AU2004255393B2/en not_active Expired
-
2011
- 2011-04-08 US US13/083,385 patent/US8241610B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20060121128A (ko) | 2006-11-28 |
| EP1648504A2 (de) | 2006-04-26 |
| KR100992646B1 (ko) | 2010-11-05 |
| WO2005004911A3 (en) | 2005-02-17 |
| US20060286128A1 (en) | 2006-12-21 |
| AU2004255393A1 (en) | 2005-01-20 |
| ES2285466T3 (es) | 2007-11-16 |
| EP1648504B1 (de) | 2007-03-21 |
| DK1648504T3 (da) | 2007-07-30 |
| DE602004005460T2 (de) | 2008-05-08 |
| DE602004005460D1 (de) | 2007-05-03 |
| WO2005004911A2 (en) | 2005-01-20 |
| US20110250224A1 (en) | 2011-10-13 |
| AU2004255393B2 (en) | 2009-12-10 |
| CA2531825C (en) | 2010-09-07 |
| US8241610B2 (en) | 2012-08-14 |
| CA2531825A1 (en) | 2005-01-20 |
| WO2005004911B1 (en) | 2005-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004005460D1 (de) | Adjuvanskombinationen von liposomen und mycobakteriellen lipiden für immunisierungszusammensetzungen und impfstoffe | |
| NZ717594A (en) | Oil-based adjuvants | |
| SE0301998D0 (sv) | Quil A fraction with low toxicity and use thereof | |
| MX375202B (es) | Composiciones adyuvantes novedosas. | |
| ATE426412T1 (de) | Adjuvante influenza-vakzine | |
| MX393384B (es) | Adyuvantes sinteticos de glucopiranosil-lipido. | |
| IN2014DN08830A (de) | ||
| MX2009003325A (es) | Vacuna que comprende un adyuvante de emulsion de aceite en agua. | |
| MY145943A (en) | Vaccine compositions comprising a saponin adjuvant | |
| WO2016179034A3 (en) | Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs | |
| MX2016009072A (es) | Fusion de antigenos micobacterianos heterooligomericos. | |
| BRPI0520330B8 (pt) | adjuvante a base de ácido polinosínico-policitidílico | |
| SG10201808315UA (en) | Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin | |
| GB201113570D0 (en) | Vaccine | |
| MX2010002866A (es) | Capas de mycoplasma gallisepticum atenuadas. | |
| WO2008148057A3 (en) | Cationic lipids compositions and methods for enhancing immune responses to vaccines | |
| BR112017005524A2 (pt) | segmentos de rna viral como agentes imunomoduladores e componentes de vacina | |
| MA46310A1 (fr) | Composition de vaccin contre le zona | |
| CA2691840C (en) | The use of monomycolyl glycerol (mmg) as an adjuvant | |
| AR069087A1 (es) | Cepa bacteriana de m. bovis atenuada avirulenta obtenida por pases, vacuna de micoplasma boris y metodos de uso de la misma | |
| ATE392216T1 (de) | Mycobakterieller impfstoff | |
| MX2017013564A (es) | Formulaciones de glucopiranosil lipido a y alérgenos de cacahuete para administración sublingual. | |
| MX2009010347A (es) | Vacunas mejoradas contra bordetella pertussis en mutantes de glicosiltransferasas lps. | |
| EA201291449A1 (ru) | Вакцинная композиция на основе стихолизина, инкапсулированного в липосомы | |
| PH12022550081A1 (en) | Ehrlichia vaccines and immunogenic compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |